Register for our free email digests:
Innoviva Inc.
www.inva.com
Latest From Innoviva Inc.
Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval
AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.
Pipeline Watch: Phase III Progress With Eylea, Tecentriq And HTX-011
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Target's NASH Study Captures Real World Data, Helps Partners With Trial Design
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease; Target PharmaSolutions conducting similar efforts in primary biliary cholangitis, hepatocellular carcinoma, and inflammatory bowel disease.
GSK's Triple Combo COPD Drug Gets Europe Okay
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Respiratory, Pulmonary
- Alias(es)
- Advanced Medicine Inc.
- Theravance Inc.
- Theravance Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Innoviva Inc.
- Senior Management
-
Michael W Aguiar, Pres. & CEO
Eric d'Esparbes, SVP, CFO
Michael Faerm, SVP, CBO
George B Abercrombie, SVP, Chief Commercial Officer
Theodore J Witek, SVP, CSO - Contact Info
-
Innoviva Inc.
Phone: (650) 238-9600
2000 Sierra Point Pkwy.
Ste. 500
Brisbane, CA 94005
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice